Objective: Patients with nonfunctional pancreatic neuroendocrine tumors (NF-PNETs) have poorer survival than those with functional PNETs. Our objective was to identify risk factors for recurrence after resection to better define surveillance parameters to improve long-term outcomes. Methods: A retrospective analysis was performed for NF-PNET patients who underwent resection at the University of Michigan from 1995 to 2012. Immunohistochemical staining of tissues from patients with and without disease recurrence was performed for Ki-67 and the macrophage marker CD68, as tumor-associated macrophages are important for PNET development and progression. Clinicopathological factors and patient outcomes were measured. Results: Ninety-seven NF-PNET patients underwent surgical resection. There was a recurrence rate of 14.4% (14/97). The median time to recurrence was 0.61 years, with 10 (71%) patients recurring within the first 2 years. Six of 7 patients (86%) monitored at 6-month surveillance intervals were diagnosed with recurrence on their first computed tomographic scan or during the intervening intervals. By Cox proportional hazards analysis, the most significant independent risk factors for recurrence were higher grade, stage, and intraoperative blood loss. High CD68 score and Ki-67 index correlated with recurrence risk, and Ki-67 index inversely correlated with time to recurrence. In patients who otherwise had few risk factors, a high CD68 score was a significant prognostic factor for recurrence. Conclusions: In patients with NF-PNETs, risk factors associated with recurrence were high EBL, grade, stage, CD68 score, and Ki-67 index. The CD68 score was an important prognostic factor in patients who otherwise had few clinicopathological risk factors; therefore, the CD68 score should be considered when planning surveillance strategies. We recommend that NF-PNET patients at high risk of recurrence undergo initial surveillance every 3 months for 2 years after surgery.
tumors. 2, 3 Nonfunctional pancreatic neuroendocrine tumors (NF-PNETs) do not produce a hormonal hypersecretion syndrome 2 and comprise 47% to 90% of all PNETs, [2] [3] [4] with an incidental detection rate of 35% to 88%. 5, 6 Because of the lack of hormonally related clinical symptoms, patients tend to be diagnosed later in the course of their disease. 7, 8 Overall, as compared with functional PNETs, NF-PNETs have a worse prognosis and poorer survival, but whether this is due to a difference in biologic aggressiveness or later diagnosis is unclear. [8] [9] [10] [11] [12] [13] [14] The mainstay of treatment for curing NF-PNETs is oncologic resection. 2 However, localized resection, such as enucleation and central pancreatectomy, may be carefully considered in incidentally found NF-PNETs smaller than 2 cm, which have a low risk of malignancy, or in patients with hereditary syndromes at high risk of multifocal/recurrent disease, including multiple endocrine neoplasia type 1 (MEN1) and Von Hippel-Lindau disease. 1, 2, 15 Long-term outcomes after surgery vary widely, with recurrence rates ranging from 17% to 76% [16] [17] [18] [19] and overall survival ranging from 1.9 to 10.3 years, 20, 21 largely depending on the extent of disease and the biologic characteristics of the tumor. Median time to recurrence has been reported to be 2 to 3.3 years. 16, 18, 22, 23 Although there have been no large-scale studies specifically investigating the factors that correlate with NF-PNET recurrence, there have been several studies identifying prognostic factors for poor overall survival. These include both clinical and histopathological factors, including weight loss, 21 older age, 24 lymph node and distant metastases, 21, 24 poor differentiation status, 21 high grade, 24 Ki-67 index greater than 5%, 21 World Health Organization classification, 25 and positive margins. 10 Genomics studies have also reported the absence of MEN1, DAXX, and ATRX mutations 26 and differential expression of such genes as KIT 27 and FGF13, TSC2, and PTEN 28 as correlating with worse survival.
The role of tumor-associated macrophages (TAMs) in tumor initiation and progression is complex, with varied pro-and antitumor-promoting effects in different types of cancers. 29 Previous studies have demonstrated that tumor-promoting behaviors are triggered in response to peritumoral hypoxia, which results in the production of a number of mitogens, growth factors, and enzymes that promote angiogenesis and tumor growth. [29] [30] [31] [32] [33] [34] TAMs have been associated with poor prognosis and malignant progression in several malignancies, such as breast cancer, prostate cancer, thyroid cancer, and Hodgkin's lymphoma. [35] [36] [37] [38] [39] Recently, it has also been demonstrated that TAMs play an important role in PNET development, using a transgenic PNET mouse model with diminished TAMs, which developed significantly fewer PNETs compared with the control model. 40 They also demonstrated that extent of TAM infiltration in 27 PNET tissue samples could be measured by immunohistochemical staining with the macrophage marker CD68 and that higher CD68 score correlated with higher tumor grade, stage, and liver metastases. 40 There are limited data to support recommendations of how NF-PNETs should be monitored after surgery. 1 The National Comprehensive Cancer Network recommends initial surveillance at 3 to 12 months postresection, then every 6 to 12 months for the next 10 years for all PNETs (regardless of function). 41 Similarly, the European Neuroendocrine Tumor Society guidelines provide a minimal consensus recommendation of surveillance every 6 to 12 months, though the authors recommend that this interval "should be adjusted to the type of tumor and the stage of the disease." 2 In randomized, multicenter trials of patients with advanced PNET disease, improved progression-free survival has been demonstrated with use of the mTOR inhibitor everolimus, 42 the tyrosine kinase inhibitor sunitinib, 43 and both streptozocin-based 44, 45 and temozolomide-based chemotherapy. [46] [47] [48] [49] Given the availability of such successful therapies, it is possible that earlier diagnosis of tumor recurrence may improve long-term outcomes. Our objective was therefore to better define risk factors for disease recurrence and parameters to help refine strategies for postoperative surveillance.
METHODS

Patients and Clinical Chart Review
A retrospective analysis was carried out for all patients who underwent pancreatic resection at the University of Michigan from June 1995 to November 2012 to identify patients with clinically nonfunctional PNETs. This study was approved by the University of Michigan institutional review board. Clinicopathological variables were reviewed and recorded, including patient demographics, clinical presentation, medical history, tobacco and alcohol use, family history, neoadjuvant and adjuvant therapy, type of resection, postoperative course, histologic findings, and survival.
Immunohistochemistry
Tissue samples were obtained from the University of Michigan Department of Pathology. Formalin-fixed, paraffin-embedded blocks were retrieved from all 14 patients with recurrent NF-PNET, from both the primary resections and any subsequent operative procedures to resect recurrent or metastatic disease. Formalin-fixed, paraffinembedded blocks were also obtained from 24 patients with nonrecurrent disease who had similarly matched clinical and histologic characteristics. Slides (4-μm thick) from the 2 blocks with the highest tumor content for each sample were used for immunohistochemical staining and evaluated in duplicate and in a blinded manner.
Primary monoclonal mouse antibodies against Ki-67 (1:100 dilution; Dako, Carpinteria, CA) and the monocyte/macrophage marker CD68 (1:200 dilution; Dako, Carpinteria, CA) were used for immunohistochemical analysis. Slides were deparaffinized in xylene and rehydrated through graded ethanol. The slides were subjected to antigen retrieval via microwaving in Antigen Retrieval Citra Plus Solution (BioGenex, Fremont, CA). Slides were quenched with 0.6% hydrogen peroxide in methanol. Nonspecific binding was blocked by incubation in 1% bovine serum albumin (BSA; Sigma-Aldrich, St Louis, MO) in phosphate-buffered saline. Slides were then incubated with primary antibodies overnight at 4 • C. Slides incubated with 1% BSA without primary antibody served as negative controls. For detection, slides were incubated with biotinylated goat antimouse immunoglobulin G (1:300 dilution; Vector Labs, Burlingame, CA), detected with VECTASTAIN Elite ABC Reagent (Vector Labs, Burlingame, CA) and Vector DAB substrate (Vector Labs, Burlingame, CA), and counterstained with hematoxylin (Sigma-Aldrich, St Louis, MO). CD68 staining was scored blindly from 1 to 3 for degree of tumor-associated macrophage infiltration as previously described. 40 Ki-67 percentage was scored blindly on the basis of 2000-cell counts. 50
Statistical Analysis
Statistical analysis was carried out using R (www.r-project. org) and GraphPad Prism software (GraphPad Software, Inc., La Jolla, CA). Statistical significance was calculated using a Fisher exact test or χ 2 test for categorical variables and Mann-Whitney U test for continuous variables. A stepwise Cox proportional hazards model was used for multivariate analysis. Disease-free survival was analyzed by Kaplan-Meier analysis and log-rank test. Wilcoxon matched-pairs signed rank test was used to correlate Ki-67 index to time to recurrence and to compare immunohistochemistry (IHC) scores of primary and metastatic/recurrent tumors. Statistical significance was defined as P < 0.05.
RESULTS
A total of 196 PNETs were resected at our institution from June 1995 to November 2012. Of these, 99 patients (50.5%) had NF-PNETs. Two patients had palliative resections for biliary decompression and relief of sinistral hypertension, respectively, and were excluded from further analysis. The remaining 97 patients had intended curative resection. Median follow-up was 2.18 years (range: 0.04-14.5 years; the patient last seen at 1 month postoperatively elected to have surveillance elsewhere). Fourteen NF-PNET patients (14.4%) experienced recurrence with a median time to recurrence of 0.61 years and a range from 0.08 to 10.16 years. Nine patients (64.3%) recurred as a liver metastasis, whereas 3 patients (21.4%) recurred in the remaining pancreas. The other 3 patients recurred in the lung, omentum, and peritoneum.
Of the 14 recurrences, 1 patient was diagnosed with liver metastasis on magnetic resonance imaging less than 1 month postoperatively during a workup for superior mesenteric vein thrombosis; this patient likely had occult metastasis at the time of his initial surgery, which had not been appreciated during preoperative staging. Two patients did not follow the recommended surveillance schedule and were lost to follow-up until diagnosis of their recurrent disease. One patient, who had MEN1, was followed yearly with endoscopic ultrasonography after complete resection of his multifocal disease, until a recurrent tumor was diagnosed 10.16 years later. The remaining 10 patients were initially followed at 3-or 6-month intervals with computed tomography (CT) and/or octreotide scan, with or without serum chromogranin A. Of the 4 patients followed with 3-month surveillance intervals, all recurrences were diagnosed on surveillance imaging. Of the 6 patients followed with 6-month surveillance intervals, recurrent disease was diagnosed on the first surveillance CT scan in 3 patients and during the intervening intervals in 2 patients; the remaining patient was diagnosed on his 2.5-year surveillance scan.
Seven (50%) of the patients with recurrence underwent surgical reresection or metastasectomy. Of these 7 patients, 2 transferred their care, and 2 died from multiorgan system failure and acute myocardial infarction, respectively. Two patients experienced disease recurrence and have remained stable on cisplatin/gemcitabine therapy and sunitinib at 1 and 2.6 years from the time of diagnosis of recurrence. The remaining patient underwent 3 additional surgeries for recurrent disease in the pancreatic bed and for liver metastasis. She remains disease-free 2 years after her last resection (8 years from her primary resection). Next, clinicopathological characteristics of patients who did and did not experience recurrence after surgical resection were compared for statistical significance (Table 1) . group and 20 to 85 years old in the nonrecurrence group [P = NS (nonsignificant)]. There were no differences in race (P = NS).
Clinical Factors
At the time of initial clinical presentation, 29% of patients who subsequently developed recurrent disease complained of persistent nausea, versus 5% in the nonrecurrence group (P = 0.01; Table 1 ). There were otherwise no differences in abdominal pain, diarrhea, jaundice, night sweats, vomiting, or weight loss (all P = NS). There were also no differences in personal or family history of pancreaticobiliary diseases or other malignancies, including diabetes, pancreatitis, MEN1, or Von Hippel-Lindau disease (all P = NS). Active and distant history of smoking and heavy alcohol use were equivalent (P = NS).
Preoperative Imaging
All patients were preoperatively imaged with CT scan and/or MRI of the abdomen/pelvis (93%/43% recurrence vs 98%/29% nonrecurrence group; P = NS). Other diagnostic studies included ab-dominal ultrasonography (0% vs 5%; P = NS), endoscopic ultrasonography (21% vs 55%; P = 0.02), endoscopic retrograde cholangiopancreatography (7% vs 6%; P = NS), and magnetic resonance cholangiopancreatography (7% vs 4%; P = NS). On the basis of clinical suspicion, additional staging workup included octreotide scan (50% vs 13%; P = 0.01), CT of the chest (7% vs 22%; P = NS), PET scan (0% vs 5%; P = NS), and bone scan (7% vs 2%; P = NS).
Neoadjuvant Factors
There was no difference in the use of neoadjuvant chemotherapy or radiation (all P = NS). Preoperative chromogranin levels were not significantly different (median 241 recurrence vs 144 ng/mL nonrecurrence group; P = NS).
Operative Factors
There was no difference in the type of surgical resection performed in the 2 groups (P = NS). The most common operative procedure was distal pancreatectomy with splenectomy (64% recurrence group, 58% nonrecurrence group). Estimated blood loss (EBL) and use of intraoperative transfusions were significantly higher in the recurrence group (P = 0.0004 and 0.0019; Table 1 ). Average EBL was 1.68 L [range = 0.20-8.0 L; 95% confidence interval (CI) = 0.29-3.1 L] in the recurrence group, compared with 0.55 L (range = 0.01-8.0 L; 95% CI = 0.34-0.76 L) in the nonrecurrence group.
Postoperative Course
There were no differences in the rates of postoperative complications and 30-day readmissions between the 2 groups (P = NS). The most common complication was grade A pancreatic leak (21% recurrence group, 23% nonrecurrence group). One patient underwent reoperation within 30 days for washout of an intra-abdominal abscess in the nonrecurrence group. There were no differences in the use of octreotide or adjuvant chemotherapy after primary resection between the 2 groups (P = NS). Three patients in the recurrence group received adjuvant radiation after primary resection for high histologic grade and other invasive features or close margin (≤1 mm). This is compared with 2 patients in the nonrecurrence group, who received adjuvant radiation for close margin and for a high-grade lesion with positive lymph nodes (P = 0.02).
Histopathological Factors
Tumor locations were equivalent between the 2 groups (body/tail: 71% recurrence vs 63% nonrecurrence; head: 36% recurrence vs 37% nonrecurrence; P = NS). Tumor size was significantly larger in the recurrence group, with a median of 4.5 cm in the recurrence group and 2.3 cm in the nonrecurrence group (P = 0.002; Table 1 ), although there was no difference in T-stage distribution (P = NS). Poor differentiation and intermediate/high grade (based on mitotic count) were significantly higher in the recurrence group (P = 0.01 and 0.0002; Table 1 ). Presence of N1, M1, and high American Joint Committee on Cancer (AJCC) stage were also more prevalent in the recurrence group (P = 0.01, 0.008, and 0.004, respectively; Table 1 ). Of note, there were 4 patients in the recurrence group (29%) who had stage IV disease at the time of resection, as compared with 3 patients in the nonrecurrence group (4%, P = 0.008).
EBL, Histologic Grade, and Stage Are the Strongest Independent Risk Factors for NF-PNET Recurrence by Multivariate Analysis
A stepwise multivariate Cox proportional hazards analysis was performed using the 9 clinicopathological factors that were significantly associated with NF-PNET recurrence by univariate analysis (nausea, intraoperative EBL, intraoperative transfusions, tumor size, differentiation, grade, N stage, M stage, AJCC stage). EBL, histologic grade, and stage were the most significant independent risk factors for recurrence (all P < 0.05; Table 2 ).
High CD68 Score Correlates With NF-PNET Recurrence
By immunohistochemical staining, high CD68 score (IHC score 2 or 3) as compared to low CD68 score (IHC score 1) correlated with recurrence (P = 0.02; Figs. 1A, B) . At 12 years, disease-free survival was 0% in patients with high CD68 scores and 83% in patients with low CD68 scores (P = 0.04, hazard ratio = 3.2; Fig. 1C ). Additional subgroup analysis was performed in those patients who had a low predicted risk of recurrence based on the factors identified in the multivariate analysis. Clinicopathological risk factors for recurrence were defined as EBL more than 0.76 L (based on upper 95% CI in nonrecurrence group), intermediate/high grade, and stage III/IV disease. In those patients with fewer than 2 risk factors, adding CD68 score provided a better prediction of disease recurrence compared to using the combination of EBL, tumor grade, and stage alone (analysis of variance, P = 0.038). In the 7 patients who underwent surgical reresection or metastasectomy for recurrent disease, there were no significant differences in the CD68 scores of the primary and metastatic specimens (P = NS).
High Ki-67 Index Correlates With NF-PNET Recurrence and Early Time to Recurrence
Ki-67 proliferative index was significantly higher in the recurrence group (mean 12.6%, SD 23.1%) versus the nonrecurrence group (mean 1.75%, SD 2.2%), as shown in Figure 2A (P = 0.0007). In the recurrence group, higher Ki-67 index also inversely correlated with time to recurrence (P= 0.02; Figure 2B ). Increasing histologic grade (Ki-67 ≤2% low, 3% to 20% intermediate, >20% high) correlated with worse disease-free survival (Fig. 3A) . Additional Ki-67 subgroup analysis further stratified survival rates, with a 5year disease-free survival of 91% in patients with Ki-67 less than 1% and 0% in patients with Ki-67 more than 6% (Fig. 3B ). There was no significant difference in the Ki-67 indices of the primary and metastatic specimens in the patients who underwent surgical reresection or metastasectomy for recurrent disease (P = NS).
DISCUSSION
In this large-scale, single-institution study, we found a 14.4% (14/97) risk of recurrence after surgical resection of NF-PNETs, with a median time to recurrence of 0.61 years, with 71% (10/14) patients recurring within the first 2 years after surgery. Of the 6 recurrence patients initially monitored at 6-month intervals, 3 (50%) were diagnosed with recurrence on their first CT scan, and 2 (33%) were diagnosed during the intervening surveillance intervals. On the basis of these findings, we recommend that patients with a high risk of recurrence be considered for close monitoring with imaging and biochemical surveillance every 3 months for the first 2 years after surgical resection. The intervals may then be lengthened thereafter, based on the patient's clinical risk factors. We hypothesize that earlier identification of recurrent disease would allow for earlier medical and/or surgical intervention and therefore improve patient outcomes, though this strategy will need to be evaluated prospectively in future studies. We found that significant clinicopathological risk factors for NF-PNET recurrence include higher intraoperative blood loss, high tumor grade, advanced AJCC stage, high CD68 score, and high Ki-67 proliferative index. Although advanced histologic grade/Ki-67 index and stage have previously been shown to correlate with poor overall survival, 21, 24, 25 this is the first study specifically focusing on the prognostic factors that correlate with disease recurrence. It is important to Copyright © 2013 Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
note that stage was a strong predictor for recurrence, highlighting the significance of following oncologic resection principles for accurate staging. Absolute Ki-67 proliferative index was also a strong predictive factor, independent of the 2% and 20% cutoffs used in histologic grade classification (Figs. 3A, B ). This is similar to prior studies that showed that a Ki-67 index greater than 5% correlated with poor overall survival. 21, 51 In our subgroup analysis, we additionally found that 5-year disease-free survival was 91% in patients with Ki-67 less than 1% and 0% in patients with Ki-67 more than 6%, which could allow clinicians the ability to further stratify their NF-PNET patients with It has previously been reported that high TAM infiltration correlates with PNET development, as well as higher grade, stage, and distant metastasis in a small patient cohort (27 patients) . 40 This larger study specifically analyzes NF-PNETs and is the first to show a correlation between TAM infiltration and risk of NF-PNET recurrence. CD68 score serves as a useful biomarker for recurrent disease, especially in those patients who otherwise had relatively few clinicopathological risk factors (Table 3 ). This demonstrates the potential prognostic importance of incorporating CD68 scoring into risk stratification of this disease in patients who otherwise appear at low risk for recurrence. This is the first, large-scale study analyzing disease recurrence as the clinical endpoint after surgical resection of NF-PNETs, with the specific goal of identifying risk factors for disease recurrence. Our findings of high grade, advanced AJCC stage and high Ki-67 index as strong predictors for NF-PNET recurrence after surgical resection correlate with previous studies that demonstrated the prognostic value of these factors in predicting overall survival. 5, 16, 21, 24 High intraoperative blood loss and high CD68 score as a measurement of TAM infiltration correlating with worse prognosis are new findings and have not been addressed in other reports.
Given the relatively low incidence of NF-PNETs, a major strength of this study is the large number of cases analyzed. Limitations include the single-institution and retrospective design. Utilizing the findings reported in this study, we propose as a next step to validate the significance of the recurrence risk factors identified here in a prospective, multicenter study of surgically resected NF-PNET patients. Clinical and histopathological parameters, including CD68 score, would be prospectively collected, to be correlated with postoperative recurrence and to calculate a scoring algorithm to predict a patient's likelihood and time to disease recurrence. A follow-up study would then be a multicenter, prospective trial randomizing patients to standardized postoperative surveillance versus surveillance intervals/frequency based on their clinically-defined risk to evaluate how such an optimized postoperative surveillance strategy affects patient outcomes.
CONCLUSIONS
Current recommendations for postoperative surveillance intervals after NF-PNET resection vary from 6 to 12 months. 2, 41 In our study, we found the initial 6-month interval to be inadequate for early detection of disease recurrence, whereas the majority of patients who recurred did so within the first 2 years after primary resection. We identified that factors associated with recurrence after surgery are high intraoperative blood loss, high grade, advanced AJCC stage, high Ki-67 index, and high CD68 score as a measurement of tumorassociated macrophage infiltration. On the basis of these findings, we recommend that NF-PNET patients with such risk factors should undergo initial postoperative surveillance every 3 months for the first 2 years after surgical resection.
